{"id":"NCT02100696","sponsor":"Hoffmann-La Roche","briefTitle":"A Study of the Efficacy and Safety of Etrolizumab in Participants With Ulcerative Colitis Who Have Been Previously Exposed to Tumor Necrosis Factor (TNF) Inhibitors","officialTitle":"Phase III, Double-Blind, Placebo-Controlled, Multicenter Study of the Efficacy and Safety of Etrolizumab During Induction and Maintenance in Patients With Moderate to Severe Active Ulcerative Colitis Who Have Been Previously Exposed to TNF Inhibitors","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-05-21","primaryCompletion":"2020-04-16","completion":"2020-04-16","firstPosted":"2014-04-01","resultsPosted":"2021-06-15","lastUpdate":"2021-08-13"},"enrollment":609,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Ulcerative Colitis"],"interventions":[{"type":"DRUG","name":"Etrozulimab","otherNames":["PRO145223","RO5490261","RG7413"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Cohort 1: Etrolizumab (Open-Label Induction (OLI) Phase)","type":"EXPERIMENTAL"},{"label":"Cohort 2: Placebo (Double-Blind Induction Phase)","type":"PLACEBO_COMPARATOR"},{"label":"Cohort 2: Etrolizumab (Double-Blind Induction Phase)","type":"EXPERIMENTAL"},{"label":"Placebo Responders: Placebo (Maintenance Phase)","type":"PLACEBO_COMPARATOR"},{"label":"Etrolizumab Responders: Placebo (Maintenance Phase)","type":"PLACEBO_COMPARATOR"},{"label":"Etrolizumab Responders: Etrolizumab (Maintenance Phase)","type":"EXPERIMENTAL"}],"summary":"This Phase III, double-blind, placebo-controlled, multicenter study will investigate the efficacy and safety of etrolizumab during induction and maintenance of remission compared with placebo in the treatment of participants with moderately to severely active ulcerative colitis (UC) who have been previously exposed to TNF inhibitors.","primaryOutcome":{"measure":"Induction Phase: Percentage of Participants With Remission at Week 14, as Determined by the Mayo Clinic Score (MCS)","timeFrame":"Week 14","effectByArm":[{"arm":"Cohort 2: Placebo (Double-Blind Induction Phase)","deltaMin":6.3,"sd":null},{"arm":"Cohort 2: Etrolizumab (Double-Blind Induction Phase)","deltaMin":18.5,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0033"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":14},"locations":{"siteCount":184,"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Canada","Czechia","Denmark","France","Germany","Greece","Hungary","Israel","Italy","Lithuania","Mexico","Netherlands","Poland","Romania","South Korea","Spain","Switzerland","United Kingdom"]},"refs":{"pmids":["34798039","32445184"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":11,"n":130},"commonTop":["Colitis ulcerative","Nasopharyngitis","Arthralgia","Headache","Fatigue"]}}